Fujifilm Opens New $9-Million Cell Culture Labs in UK
PTSM: Pharmaceutical Technology Sourcing and Management
The new 10,000 ft2 of laboratories will be dedicated to the company’s monoclonal antibody platform, which enables rapid access to development and manufacturing capacity.
On Sep. 12, 2017, Fujifilm Diosynth Biotechnologies, a biologics contract development and manufacturing organization (BioCDMO), announced the opening of its new 10,000-ft2 cell culture Process Development Laboratories in Wilton Centre, Teesside in the United Kingdom. The laboratories were built through a JPY 1-billion (US$9-million) investment, part of a greater JPY 14-billion (US$130-million) expansion announced by Fujifilm Corporation in April 2017.
The new laboratories will be dedicated to supporting activities in the Saturn mAb [monoclonal antibody] Platform. The Saturn mAb Platform is designed to enable rapid access to process development and manufacturing capacity.
“These laboratories are designed to incorporate the latest high-throughput technologies, including fully automated high throughput bioreactors and chromatography systems,” said Andy Topping, CEO, Fujifilm Diosynth Biotechnologies, in a company press release.
A grant from Let’s Grow, part of the UK government’s Regional Growth Fund, also contributed to the overall investment of the BioCDMO’s continued growth in the Tees Valley. The new facility will bring new sustainable, high-tech jobs to the region.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
